Form 8-K - Current report:
SEC Accession No. 0001213900-24-099633
Filing Date
2024-11-18
Accepted
2024-11-18 16:01:10
Documents
15
Period of Report
2024-11-14
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea022169101-8k_adialpharm.htm   iXBRL 8-K 30259
2 PRESS RELEASE ISSUED BY ADIAL PHARMACEUTICALS, INC., NOVEMBER 14, 2024 ea022169101ex99-1_adialpharm.htm EX-99.1 13550
3 GRAPHIC image_001.jpg GRAPHIC 3997
  Complete submission text file 0001213900-24-099633.txt   232178

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE adil-20241114.xsd EX-101.SCH 3051
5 XBRL LABEL FILE adil-20241114_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE adil-20241114_pre.xml EX-101.PRE 22383
17 EXTRACTED XBRL INSTANCE DOCUMENT ea022169101-8k_adialpharm_htm.xml XML 3773
Mailing Address 1180 SEMINOLE TRAIL SUITE 495 CHARLOTTESVILLE VA 22901
Business Address 1180 SEMINOLE TRAIL SUITE 495 CHARLOTTESVILLE VA 22901 434-422-9800
ADIAL PHARMACEUTICALS, INC. (Filer) CIK: 0001513525 (see all company filings)

EIN.: 800667150 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38323 | Film No.: 241471404
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)